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Combined Therapy of Dietary Fish Oil and Stearoyl-CoA
Desaturase 1 Inhibition Prevents the Metabolic Syndrome
and Atherosclerosis
J. Mark Brown, Soonkyu Chung, Janet K. Sawyer, Chiara Degirolamo, Heather M. Alger,
Tam M. Nguyen, Xuewei Zhu, My-Ngan Duong, Amanda L. Brown, Caleb Lord, Ramesh Shah,
Matthew A. Davis, Kathryn Kelley, Martha D. Wilson, Jennifer Madenspacher, Michael B. Fessler,
John S. Parks, Lawrence L. Rudel
Background—Stearoyl-CoA desaturase 1 (SCD1) is a critical regulator of energy metabolism and inflammation. We have
previously reported that inhibition of SCD1 in hyperlipidemic mice fed a saturated fatty acid (SFA)-enriched diet
prevented development of the metabolic syndrome, yet surprisingly promoted severe atherosclerosis. In this study we
tested whether dietary fish oil supplementation could prevent the accelerated atherosclerosis caused by SCD1 inhibition.
Methods and Results—LDLr/, ApoB100/100 mice were fed diets enriched in saturated fat or fish oil in conjunction with
antisense oligonucleotide (ASO) treatment to inhibit SCD1. As previously reported, in SFA-fed mice, SCD1 inhibition
dramatically protected against development of the metabolic syndrome, yet promoted atherosclerosis. In contrast, in
mice fed fish oil, SCD1 inhibition did not result in augmented macrophage inflammatory response or severe
atherosclerosis. In fact, the combined therapy of dietary fish oil and SCD1 ASO treatment effectively prevented both
the metabolic syndrome and atherosclerosis.
Conclusions—SCD1 ASO treatment in conjunction with dietary fish oil supplementation is an effective combination
therapy to comprehensively combat the metabolic syndrome and atherosclerosis in mice. (Arterioscler Thromb Vasc
Biol. 2010;30:24-30.)
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It has been estimated that nearly a quarter of Americanadults have the metabolic syndrome.1–3 Inhibition of
stearoyl-CoA desaturase 1 (SCD1) has been proposed as an
attractive strategy for preventing most aspects of the meta-
bolic syndrome including obesity,4–9 insulin resistance,4,6,10,11
hypertriglyceridemia,6,12–14 and hepatic steatosis.8,9,12,15,16
However, several unwanted side effects are associated with
SCD1 inhibition or deletion, including alopecia17–20 and
accelerated atherosclerosis.21,22 We have previously shown
that the accelerated atherosclerosis seen with SCD1 ASO-
mediated inhibition is associated with saturated fatty acid
(SFA) enrichment of macrophage membranes, and enhanced
proinflammatory signaling through toll-like receptor 4
(TLR4).21 Likely through a similar mechanism, mice lacking
SCD1 have enhanced dextran sulfate sodium (DSS)- and
bacterial-induced inflammatory gene expression and exagger-
ated colitis.23 These recent studies21–23 suggest that SCD1
may serve a protective function against proinflammatory
signaling.
It is reasonable to assume that many of the inflammation-
linked side effects seen with SCD1 inhibition stem from the
abnormal accumulation of SCD1 substrates, saturated fatty
acids, in multiple tissues. Indeed, there is a large body of
evidence that SFAs are potent proinflammatory molecules,
linking these SCD1 substrates to a number of inflammatory
diseases.24–34 In fact, recent evidence suggests that SFAs can
activate multiple toll-like receptors (TLRs), which play a key
role in innate immunity.24,28,29,31–34 Furthermore, TLR4 is
necessary for SFAs to induce obesity, insulin resistance, and
vascular inflammation in rodents.24–27 Therefore, one of the
key roles of SCD1 may be to suppress inflammation by
preventing excessive accumulation of SFA-derived TLR4
ligands. Interestingly, long chain -3 polyunsaturated fatty
acids (-3 PUFA) have been shown to counteract SFA-
induced TLR4 activation in cultured macrophage and den-
dritic cell systems.28,30–33 In parallel, there is strong evidence
that dietary -3 PUFA supplementation can effectively blunt
inflammation and related diseases in vivo.34–36 Therefore, we
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reasoned that dietary supplementation with fish oil–derived
-3 PUFAs may prevent the SFA-driven TLR4 hypersensi-
tivity and accelerated atherosclerosis seen with SCD1
inhibition.21
Methods
Male low-density lipoprotein receptor–deficient (LDLr/), apoli-
poprotein B 100 only (ApoB100/100) mice were treated with antisense
oligonucleotides (ASOs) to inhibit SCD1 while consuming diets
containing 0.1% (w/w) cholesterol and 12% of energy as primarily
either SFA-enriched fat (palm oil) or long chain -3 PUFA-enriched
fat (fish oil) for 20 weeks as previously described.21 Detailed
descriptions of diets, materials, and experimental methods are
available in the supplemental materials (available online at
http://atvb.ahajournals.org).
Results
SCD1 ASO Treatment and Dietary Fish Oil
Reduce SCD1 Expression in a Tissue-Specific
Manner, Resulting in Protection Against
Diet-Induced Obesity and Insulin Resistance
There is a large body of evidence that either SCD1 inhibition
or dietary fish oil alone can protect against diet induced
obesity and insulin resistance in rodents.4–11,30–36 However,
the possibility that the combination of these 2 treatments can
act synergistically to improve the metabolic syndrome has
never been addressed. Interestingly, both SCD1 ASO treat-
ment and dietary fish oil can diminish SCD1 expression in a
tissue-specific manner (supplemental Figure 1), resulting in
dramatic protection against diet-induced obesity and insulin
resistance (supplemental Figure 2). A detailed description of
these anticipated metabolic improvements is provided in the
supplemental materials.
Dietary Fish Oil Supplementation Prevents SCD1
ASO-Driven Atherosclerosis
We have previously shown that the SCD1 inhibition in
hyperlipidemic mice fed either SFA-rich or monounsatu-
rated fatty acid (MUFA)-rich diets results in more exten-
sive atherosclerosis.21 This unforeseen side effect of SCD1
inhibition was associated with SFA enrichment of plasma
lipids and macrophage membranes, together with enhanced
TLR4-driven proinflammatory signaling. Importantly,
long chain -3 PUFAs have been shown to prevent
SFA-induced TLR4 activation in cultured cells.28,31–34
Therefore, we set out to test whether this relationship held
up in vivo by examining atherosclerosis, a complex disease
with an inflammatory component that is promoted by both
Figure 1. Dietary fish oil supplementa-
tion prevents SCD1 ASO-driven athero-
sclerosis in LDLr/, ApoB100/100 mice.
Starting at 6 weeks of age, male mice
were fed diets containing 0.1% (w/w)
cholesterol enriched in either saturated
(Sat.) or long chain -3 fatty acids (Fish)
for 20 weeks in conjunction with
biweekly injections (25 mg/kg) of a non-
targeting control ASO f or SCD1 ASO
. A. En face morphometric analysis of
total aortic lesion area. Data shown in
panel A represent the meanSEM from
6 mice per group. GLC analysis of aortic
cholesteryl ester (B) and free cholesterol
(C) was determined. Data in panels B
and C represents the meanSEM from 8
to 15 mice per group. Values not sharing
a common superscript differ significantly
(P0.05). D, Representative Verhoeff–van
Giesen stained sections of proximal aor-
tae from mice treated with diet and ASO
for 20 weeks. E, Representative hema-
toxylin and eosin–stained sections of
proximal aortae from mice treated with
diet and ASO for 20 weeks.
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SFA37,38 and TLR4 activation.39,40 As previously demon-
strated, en face morphometric analysis showed that SCD1
ASO treatment in mice fed a SFA-rich diet resulted in a
2.7-fold increase in total aortic lesion area, compared to
mice treated with a control ASO (Figure 1A). In parallel,
SCD1 inhibition in mice fed a SFA-rich diet also resulted
in increased concentrations of aortic cholesteryl ester
(Figure 1B), aortic free cholesterol (Figure 1C), and
abundant areas of necrosis with visible cholesterol crystals
(Figure 1D), all indicating accelerated atherosclerosis. In
contrast, in mice fed a fish oil diet, SCD1 ASO treatment
had no significant effects on lesion area (Figure 1A), aortic
cholesteryl ester (Figure 1B), and aortic free cholesterol
(Figure 1C), or lesion complication (Figure 1D and 1E),
compared to control ASO treated mice. The chemical
measurement may have been the most precise quantifica-
tion of atherosclerosis, and mice fed a fish oil diet had
significantly less aortic cholesteryl ester, compared to
SFA-fed mice regardless of ASO treatment (Figure 1B).
After 20 weeks of induction, the rank order of aortic
cholesteryl ester for the groups was: SFA-fed/SCD1 ASO
(118 g/mg protein)SFA-fed/Control ASO (73 g/mg
protein)Fish-oil fed/Control ASO (29 g/mg
protein)Fish oil-fed/SCD1 ASO (5 g/mg protein).
Dietary Fish Oil Supplementation and SCD1 ASO
Treatment Improve Atherogenic Hyperlipidemia
in a Complimentary Fashion
In agreement with previous reports,6,12–14 SCD1 inhibition
alone and dietary fish oil alone prevented diet-induced
hypertriglyceridemia, which was apparent after only 4 weeks
of either treatment (Figure 2A). After 8 weeks of treatment,
the rank order of the groups for plasma TG was: SFA-fed/
Control ASO (201 mg/dL)SFA-fed/SCD1 ASO (118 mg/
dL)Fish oil-fed/Control ASO (113 mg/dL)Fish oil-fed/
SCD1 ASO (76 mg/dL). In contrast to plasma TG, SCD1
ASO treatment only modestly reduced total plasma choles-
terol (TPC) after 20 weeks in mice fed the SFA diet. TPC was
not significantly altered after 4 or 8 weeks of this treatment
(Figure 2B). Furthermore, in the fish oil–fed group, SCD1
ASO treatment did not produce a TPC lowering effect (Figure
2B). When lipoprotein cholesterol distribution was analyzed,
we discovered that SCD1 inhibition alone and fish oil feeding
alone decreased VLDL cholesterol compared to their respec-
tive controls (Figure 2C), but the 2 treatments together were
not synergistic in lowering VLDLc. Interestingly, SCD1 ASO
treatment had no effect on LDLc regardless of diet (Figure
2D). In contrast, dietary fish oil significantly reduced LDLc,
compared to SFA-fed groups, regardless of ASO treatment
(Figure 2D). Furthermore, both SCD1 ASO treatment and
dietary fish oil caused significant reductions in plasma HDLc
(Figure 2E). As previously described,21 SCD1 ASO treatment
caused marked enrichment of LDL cholesteryl esters (LDL-
CE) with saturated FA in both diet groups (Figure 2F). Also,
dietary fish oil supplementation resulted in the expected -3
PUFA-enrichment in LDL-CE (Figure 2F). Interestingly,
ASO-mediated inhibition of SCD1 in fish oil–fed mice
caused significantly more -3 PUFAs to be incorporated in
LDL-CE, compared to control ASO treated mice. It seems the
primary effects of SCD1 inhibition alone are: diminished
plasma triglyceride, decreased VLDLc, and enrichment of
plasma lipoproteins with SFA. In contrast, dietary fish oil
effectively reduces both plasma TG and LDLc levels. Col-
lectively, the effects of SCD1 ASO and dietary fish oil
synergistically improve atherogenic hyperlipidemia, likely
through independent mechanisms.
Dietary Fish Oil Supplementation Prevents SCD1
ASO-Driven TLR4 Hypersensitivity
in Macrophages
SCD1 ASO treatment for 6 weeks reduced the palmitoleate
(16:1) to palmitate (16:0) ratio in macrophage PL in both
diet groups (Figure 3A). This was anticipated because we
have previously demonstrated that SCD1 ASO treatment
reduces macrophage SCD1 expression.21 Dietary fish oil
Figure 2. Combined therapy of dietary
fish oil and SCD1 ASO synergistically
improves hyperlipidemia in LDLr/,
ApoB100/100 mice. Starting at 6 weeks
of age, male mice were fed diets con-
taining 0.1% (w/w) cholesterol enriched
in either saturated (Sat.) or long chain
-3 fatty acids (Fish) for 20 weeks in
conjunction with biweekly injections (25
mg/kg) of a nontargeting control ASO
(Control) or SCD1 ASO (SCD1). Plasma
samples were collected at baseline (6
weeks of age), and after 4, 8, or 20
weeks of diet and ASO treatment.
Plasma triglycerides (A) and total
plasma cholesterol (TPC; B) were measured enzymatically. Data
shown in panels A and B represents the meanSEM from 5 to
8 mice per group, *significantly different than the saturated diet
fed control ASO treated group, within each time point (P0.05).
Panels C through E represent cholesterol levels in very low–
density lipoproteins (VLDLc), low-density lipoproteins (LDLc),
and high-density lipoproteins (HDLc) in mice receiving dietary
and ASO treatment for 20 weeks. Data shown in panels C
through E represent the meanSEM from 6 mice per group,
and values not sharing a common superscript differ significantly
(P0.05). F, Fatty acid (FA) composition (% of total FA as satu-
rated or long chain -3 [eicosapentaenoic and docosahexae-
noic] fatty acids) of LDL cholesteryl esters (LDL CE-FA). Data
shown in panel F represent the meanSEM (n5 per group),
and values not sharing a common superscript differ significantly
(P0.05).
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alone did not alter the 16:1 to 16:0 ratio in macrophage PL,
compared to PL isolated from SFA-fed mice (Figure 3A),
and did not alter macrophage SCD1 mRNA levels (Figure
3C). However, dietary fish oil supplementation resulted in
expected -3 PUFA-enrichment in macrophage PL (Figure
3A). As seen in plasma (Figure 2F) and the liver (supple-
mental Figure 3D), ASO-mediated inhibition of SCD1 in
mice fed a fish oil diet caused a trend toward increased -3
PUFA incorporation into macrophage PL, compared to
control ASO-treated mice. It has previously been demon-
strated that macrophage SCD1 plays a role in cellular
cholesterol efflux,41 which could subsequently impact
atherogenesis. However, we did not see any appreciable
effects of diet or SCD1 ASO treatment on cellular choles-
terol efflux to either lipid-free apoAI or HDL (Figure 3B).
More importantly, when macrophages isolated from SCD1
ASO-treated mice fed a SFA-rich diet were challenged
with a specific TLR4 agonist (10 ng/mL Kdo2-Lipid A),
marked hypersensitivity was apparent, both at the mRNA
level (Figure 3C) and the level of protein secretion (Figure
3D) as previously described.21 In support of this, TLR4-
dependent upregulation of inflammatory gene expression
Figure 3. Dietary fish oil supplementation prevents SCD1 ASO-driven TLR4 hypersensitivity in macrophages. Starting at 6 weeks
of age, male mice were fed diets containing 0.1% (w/w) cholesterol enriched in either saturated (Sat.) or long chain -3 fatty
acids (Fish) for 6 weeks in conjunction with biweekly injections (25 mg/kg) of a nontargeting control ASO (Cont.) or SCD1 ASO
(SCD1). After 6 weeks of diet and ASO treatment, freshly isolated thioglycollate-elicited macrophages were pooled (n5 to 7 mice
per pool) and cultured as described in materials and methods. A, Phospholipid fatty acid (PL-FA) composition (16:1 to 16:0 ratio
and % of total FA as long chain -3 [eicosapentaenoic and docosahexaenoic] fatty acids) of freshly isolated (2-hour culture) mac-
rophages. B, Macrophage cholesterol efflux to apoAI (10 g/mL) or high-density lipoprotein (HDL, 50 g/mL). C, TLR4-driven
gene expression: Freshly isolated macrophages were treated with vehicle or 10 ng/mL Kdo2-Lipid A (TLR4 agonist) for 6 hours,
and mRNA levels were measured for interleukins 1 beta (IL-1), 6 (IL-6), and 12p40 (IL-12p40), tumor necrosis factor  (TNF),
C-X-C motif ligand 10 (IP-10), and gluocorticoid attenuated response gene 16 (Garg-16), and normalized to GAPDH. Data shown
in panel C are expressed as the mean relative mRNA expression, where all values were normalized to the levels in the Sat. – Con-
trol vehicle treated group, and the SEM was calculated from triplicate plates for each pool. D, TLR4-driven cytokine secretion:
Freshly isolated macrophages were treated with vehicle or 10 ng/mL Kdo2-Lipid A (TLR4 agonist) for 6 hours, and cytokine levels
(pg/mL) were measured for IL-1, IL-6, IL-12p40, TNF, Chemokine C-X-C motif ligand 1 (KC), Regulated on Activation Normal
T-cell Expressed and Secreted (RANTES,) monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1
alpha (MIP-1) using conditioned media. Data shown in panel D the meanSEM from triplicate plates for each pool. N.D. indi-
cates values not detectable.
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was much more robust in macrophages isolated from
SFA-rich diet–fed mice treated with SCD1 ASO, compared
to macrophages isolated from their counterparts treated
with control ASO (Figure 3C). Likewise, TLR4-dependent
promotion of inflammatory cytokine secretion was much
more robust in macrophages isolated from SFA-rich diet–
fed SCD1 ASO-treated mice, compared to macrophages
isolated from their counterparts treated with control ASO
(Figure 3D). In contrast, in mice fed a -3 PUFA-rich diet,
SCD1 ASO treatment did not result in TLR4 hypersensi-
tivity (Figure 3C and 3D). Interestingly, plasma levels of
inflammatory cytokines were relative low in all the exper-
imental groups (supplemental Table II) and were not
significantly different with SCD1 ASO treatment. Collec-
tively, these data suggest that SCD1 ASO-driven TLR4
hypersensitivity in macrophages can be prevented by
dietary fish oil supplementation.
Combined Therapy of Dietary Fish Oil and SCD1
ASO Prevents Diet-Induced Hepatic Steatosis
Mice lacking SCD1 are protected against diet- and
genetically-induced hepatic steatosis.13,14,17,20,21 Likewise, di-
etary -3 PUFA supplementation protects against hepatic
steatosis in a number of experimental models.6,22 Interest-
ingly, the dual therapy of dietary fish oil and SCD1 ASO
treatment resulted in near complete prevention of diet-
induced hepatic steatosis (supplemental Figure 3). A detailed
description of these data are provided in the supplemental
material.
Discussion
The search for metabolic syndrome targets has strongly
supported SCD1 inhibitors as an attractive option for prevent-
ing obesity, insulin resistance, hypertriglyceridemia, and
hepatic steatosis.4–16 Unfortunately, there are severe side
effects associated with diminished SCD1 activity in mice,
including skin pathology17–20 and accelerated atherosclero-
sis.21,22 These warning signs have unfortunately impeded
many SCD1 inhibitor programs,42 without complete under-
standing of the etiology of these complex side effects. It is
logical to assume many of the side effects seen with SCD1
inhibition stem from the abnormal accumulation of SFAs
in multiple tissues. Indeed, SFAs are potent proinflamma-
tory molecules24 –34 and have been linked to innate immu-
nity.24,28,29,31–34 Therefore, SCD1 may indirectly suppress
inflammation by preventing SFA-induced activation of
TLR4. The concept of fatty acids regulating inflammation
is not unique to SFAs. In fact, long chain -3 PUFA from
fish oil have been shown to inhibit inflammation, and more
importantly, counteract SFA-induced TLR4 activation in
cultured cells.28,30 –33 This study provides new evidence
that this reciprocal relationship between SFA and -3
PUFA in modulating inflammation also holds true in vivo,
and can be exploited to protect against multiple metabolic
diseases.
The question now becomes: how does the combination
of SCD1 ASO treatment and dietary fish oil synergize to
comprehensively prevent the development of obesity, in-
sulin resistance, hyperlipidemia, hepatic steatosis, and
atherosclerosis? There are likely both shared and indepen-
dent mechanisms by which these treatments mediate their
effects. When given as a monotherapy, SCD1 ASO treat-
ment results in striking protection against diet-induced
obesity,7,21 insulin resistance,7,10,21 hypertriglyceride-
mia,7,21 and hepatic steatosis.7,21 Unfortunately, SCD1
ASO treatment promotes severe atherosclerosis in hyper-
lipidemic mice fed either a SFA- or MUFA-rich diet.21 We
believe that dietary fish oil supplementation is able to
prevent SCD1 ASO-driven atherosclerosis through at least
3 independent mechanisms: (1) lowering LDLc, (2) enrich-
ing the remaining LDL-CE in atheroprotective -3
PUFAs, and (3) counteracting SFA-driven inflammation.
In support of this, dietary fish oil lowered LDLc by 47% to
53%, compared to SFA-fed mice regardless of ASO
treatment (Figure 2D). However, the LDL-CE remaining in
fish oil fed mice treated with SCD1 ASO was highly
enriched in -3 PUFAs, yet enriched in SFA to the same
extent as SFA-fed SCD1 ASO-treated mice (Figure 2F).
These results indicate that dietary fish oil does not dimin-
ish SCD1 ASO-mediated SFA enrichment of plasma lipids,
but rather shifts the fatty acid composition to be more
polyunsaturated, which has the potential to diminish the
production of VLDLc45 (Figure 2C). In this regard, it has
been previously demonstrated that long chain fatty acids
such as docosahexaenoic acid (DHA) can inhibit VLDL
secretion by promoting post-ER presecretory proteolysis
(PERPP)-mediated degradation of apolipoprotein B46 or
endoplasmic reticulum (ER) stress–related degradation of
apoB.47 Although we did not directly measure oxidant
stress or PERPP, we saw no indication that either fish oil
or SCD1 ASO promoted hepatic ER stress (supplemental
Figure 4).
It is important to note that SCD1 ASO treatment unexpect-
edly results in a dramatic HDLc reduction in hyperlipidemic
mice fed a SFA-rich diet.21 Based on this, it has recently been
speculated that SCD1 ASO-driven HDLc lowering may be
the cause of accelerated atherosclerosis seen under these
conditions.22 However, our data suggest that HDLc lowering
plays little, if any, role in SCD1 ASO-driven accelerated
atherosclerosis. In support of this, dietary fish oil alone
actually decreased HDLc, compared to SFA-fed mice (Figure
2E), yet atherosclerosis was also decreased in fish oil–fed
mice. Most importantly, fish oil supplementation did not
prevent SCD1 ASO-mediated reductions in HDLc seen in
SFA-fed mice (Figure 2E). In fact, the mice treated with
SCD1 ASO and fed dietary fish oil had the lowest HDLc of
any group with the rank order of the 4 groups being:
SFA-fed/Control ASO (79 mg/dL)Fish oil-fed/Control
ASO (49 mg/dL)SFA-fed/SCD1 ASO (35 mg/dL)Fish
oil-fed/SCD1 ASO (30 mg/dL). Collectively, these data
suggest that HDLc modulation is not the primary mechanism
by which dietary fish oil protects against SCD1 ASO-driven
atherosclerosis.
In addition to reducing plasma lipoprotein levels, dietary
fish oil prevents SCD1 ASO-driven TLR4 hypersensitivity
(Figure 3C). This may be attributable, in part, to the
28 Arterioscler Thromb Vasc Biol January 2010
 
enrichment of macrophage membranes with long chain -3
PUFAs (Figure 3A), which are known to prevent SFA-
driven TLR4 activation.28,30 –33 Importantly, SCD1 ASO
treatment results in marked accumulation of SFA in
plasma, multiple tissues, and isolated macrophages (Figure
2F, supplemental Figure IIID, and Figure 3A,21). However,
this SFA enrichment is not prevented by dietary fish oil
supplementation (Figure 2F, supplemental Figure IIID, and
Figure 3A). Hence, even in the face of massive SCD1
ASO-driven SFA accumulation, moderate dietary -3
PUFA supplementation can prevent SFA-driven inflamma-
tion (Figure 3C) and atherosclerosis (Figure 1). This makes
it tempting to speculate that the other diverse pathologies
associated with genetic deletion of SCD1,11,17–20,23 includ-
ing alopecia, might likewise be ameliorated by the antiin-
flammatory effects of dietary fish oil. Interestingly, during
the preparation of this manuscript, a recent study warned
that previous work29 –33 describing SFA-mediated activa-
tion of TLR4 or TLR2 may have been confounded by
contamination of the fatty acid vehicle (BSA) with LPS or
bacterial lipoproteins.48 Importantly, because in vivo di-
etary feeding of long-chain fatty acids does not require a
BSA vehicle, this is likely not the only explanation for
SFA-induced TLR4 activation. Rather, our results provide
in vivo evidence that saturated fatty acids do indeed
promote TLR4-dependent signaling and that n-3 PUFAs
can antagonize SFA-driven TLR4 hypersensitivity (Figure
3). However, whether fatty acids exert their effects through
direct TLR4 agonism or by modulating membrane organi-
zation is still a matter of debate and requires further work.
It is important to point out that ASO-mediated inhibition
of SCD1 does not alter SCD1 protein expression in the
skin or result in alopecia.21 This tissue-specific pattern of
inhibition seen with in vivo ASO administration has been
documented previously43,44 and is ideal for SCD1 inhibi-
tion where tissue specificity is required to avoid unwanted
side effects. In a recent study by MacDonald and col-
leagues,22 it was speculated that the accelerated atheroscle-
rosis seen with genetic SCD1 deficiency was in part
attributable to dermal inflammation.22 This is unlikely to
be the primary mechanism for the accelerated atheroscle-
rosis, because SCD1 ASO treatment also results in severe
atherosclerosis, without affecting skin SCD1 expression or
alopecia.21 Therefore, ASO-mediated inhibition may pro-
vide a unique tissue-specific therapeutic strategy to avoid
the skin pathology17–20 that would likely accompany small
molecule SCD1 inhibitors without tissue specificity.
In summary, we have demonstrated that SCD1 ASO
treatment protects against development of the metabolic
syndrome but unfortunately promotes atherosclerosis in
mice fed diets enriched in either SFA or MUFA.6 How-
ever, SCD1 ASO-driven atherosclerosis can be completely
prevented by dietary fish oil (Figure 1). Importantly, the
proinflammatory effects of SCD1 ASO treatment can be
overcome by dietary -3 PUFA supplementation, and the
dual therapy provides dramatic protection against athero-
genic hyperlipidemia. Therefore, this synergistic dual ther-
apy may provide a novel therapeutic approach for the
metabolic syndrome and atherosclerosis.
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Supplemental Materials and Methods 
Mice.  
Male low density lipoprotein receptor deficient (LDLr-/-), apolipoprotein B 100 only 
(ApoB100/100) mice were used in this study. These mice were chosen based on previous 
reports documenting their “human-like” lipoprotein profile1, atherosclerosis susceptibility 
1,2, and responsiveness to dietary fatty acids2. All mice were on a mixed background 
(~75% C57BL/6 and ~25% 129Sv/Jae). To inhibit SCD1, antisense oligonucleotides 
(ASOs) were given as previously described3, with minor modifications. Briefly, at 6 
weeks of age, mice were switched from rodent chow to one of two synthetic diets 
containing 12% of energy as primarily either SFA-enriched fat (palm oil) or long chain 
ω-3 PUFA-enriched fat (fish oil), with 0.1% (w/w) cholesterol added. Please refer to 
Supplemental Table 1 for quality control analysis of dietary fatty acid composition. We 
have previously published the effects of SCD1 inhibition in SFA-fed mice3, and these 
data are included here strictly for comparative purposes. All experimental animals were 
sacrificed after 20 weeks of parallel dietary and ASO treatment, except for macrophage 
experiments where mice were sacrificed after 6 weeks of treatment. Mice were 
maintained in an American Association for Accreditation of Laboratory Animal Care-
approved pathogen-free animal facility, and all experimental protocols were approved by 
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Plasma Lipid and Lipoprotein Analyses. Plasma samples were collected by 
submandibular vein puncture at baseline (6 weeks of age chow fed animals), and after 4, 
8, or 20 weeks of diet and ASO treatment. Detailed description of plasma lipid analyses 
has been previously described.3  
 
Glucose homeostasis. Intraperitoneal glucose tolerance tests (GTT) and insulin tolerance 
tests (ITT) were performed as previously described3 in mice that had been treated with 
diet and ASO for 16 weeks.  
 
Quantification of atherosclerosis. En face morphometric and biochemical quantification 
of aortic atherosclerosis was conducted as previously described3 in mice that had been 
treated with diet and ASO for 20 weeks. 
 
Hepatic lipid mass and fatty acid composition. Extraction of liver lipids and 
biochemical analyses were performed as previously described3 in mice that had been 
treated with diet and ASO for 20 weeks.  
 
Hepatic ER stress. Total liver homogenates were prepared as previously described3, and 
ER stress was measured by immunoblotting using antibodies recognizing CHOP (Cell 
Signaling Technologies # 2895), protein disulfide isomerase (PDI, Cell Signaling 
Technologies # 2446), and BIP (Cell Signaling Technologies # 3177). 
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Peritoneal macrophage isolation and culture. For macrophage studies, mice received 
diet and ASO treatment for six weeks. Thereafter, thioglycolate-elicited peritoneal 
macrophages were pooled from five mice per group, and were cultured in 35-mm dishes 
as previously described.3 For TLR4 agonist studies, following two hours of culture, 
adherent macrophage were washed three times with PBS, and subsequently maintained in  
serum free RPMI-1640 for an additional two hours to dampen basal serum-induced 
signaling. Thereafter, cells were treated with vehicle (PBS) or 10 ng/ml of the defined 
TLR 4 agonist4 Kdo2-Lipid A for six hours to examine inflammatory gene expression by 
qPCR as previously described3, and cytokine secretion was measured using a Bio-Plex 
mouse cytokine kit (Bio-Rad) using fluorescently labeled microsphere beads and a Bio-
Plex suspension array system (Bio-Rad) according the to the manufacturer's instructions. 
For cholesterol efflux, freshly isolated macrophages were incubated with 3H-cholesterol 
for 8 hours. Thereafter, cells were gently washed four times with PBS, and then 
supplemented with 1 ml of efflux medium (serum-free RPMI-1640 and 0.1% fatty-acid-
free BSA) in the absence or presence of cholesterol acceptors (10 µg/ml apoA-I or 
50 µg/ml HDL) for 6 h at 37°C. To determine cholesterol efflux, the conditioned media 
were collected and centrifuged for 5 min at 16000 g to pellet cellular debris. An aliquot 
was removed and the radioactivity present in the incubation medium was determined by 
liquid-scintillation counting. The percentage of radiolabelled cholesterol released (% 
efflux) was calculated as: (dpm in medium after 6h / dpm in cells at zero time) x 100. For 
isolated macrophage experiments, the data shown in Figure 3 are representative of one 
pool of macrophages (n=5 mice per group) split into triplicate plates, and similar results 
were seen in an independent pool of macrophages (n=5-7 mice per group). 
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SCD Activity Assay. Hepatic SCD1 activity was measured in liver microsomes as 
previously described3, in mice that had been treated with diet and ASO for 20 weeks.  
 
Quantitative Real-Time PCR (qPCR). RNA extraction and qPCR was conducted as 
previously described3 on pooled samples (n=5 per group). Messenger RNA levels for 
each gene represent the amount relative to the amount in the control ASO treated SFA 
diet-fed group, which was arbitrarily standardized to 100%. Primers used for qPCR have 
been previously described.3 
 
Statistical Analysis. Data are expressed as the mean ± standard error of the mean (SEM).  
All data were analyzed using two-way analysis of variance (ANOVA) using diet and 
ASO treatment as individual variables, followed by Student’s t tests for post hoc analysis.  
Differences were considered significant at p <0.05.  All analyses were performed using 














Dietary fish oil and SCD1 ASO treatment reduce SCD1 expression in a tissue-
specific manner. To specifically inhibit SCD1 activity, we utilized antisense 
oligonucleotide (ASO) treatment as previously described3 in low density lipoprotein 
receptor knockout (LDLr -/-), apolipoprotein B only (ApoB100/100) mice, a mouse model of 
LDL-driven atherosclerosis. Mice were fed either a SFA-rich or a ω-3 PUFA-rich diet for 
20 weeks. Regardless of diet, SCD1 mRNA levels were reduced by 99% in the liver and 
78-93% in adipose tissue in mice treated with SCD1 ASO (Supplemental Figure 1, A and 
B). In agreement, hepatic SCD1 activity was reduced by > 95% after 20 weeks of SCD1 
ASO treatment in mice fed the SFA-rich diet (Supplemental Figure 1C). As has been 
previously described5,6, when compared to SFA-feeding, dietary ω-3 PUFA 
supplementation resulted in a 75% reduction in hepatic SCD1 mRNA levels in control 
ASO treated mice (Supplemental Figure 1A). This dietary fish oil-driven reduction of 
SCD1 mRNA occcured only in the liver, and not in adipose tissue (Supplemental Figure 
1B) or macrophages (Figure 3C), indicative of tissue-specific regulation. 
 
Combination therapy of dietary fish oil and SCD1 ASO prevents diet-induced 
obesity and insulin resistance. We previously demonstrated that ASO-mediated 
inhibition of SCD1 prevented diet-induced obesity and insulin resistance in LDLr -/-, 
ApoB100/100 mice fed a SFA-rich diet.3 Likewise, it has been demonstrated that dietary 
fish oil supplementation can similarly improve obesity and insulin resistance.7,8 
Therefore, we set out to determine if the combination therapy of dietary fish oil and 
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SCD1 ASO could act synergistically to further ameliorate diet-induced obesity and 
insulin resistance. In agreement with previous reports3, SCD1 inhibition prevented diet-
induced obesity in LDLr -/-, ApoB100/100 mice fed either diet (Supplemental Figure 2, A 
and B). Following 20 weeks of treatment, epididymal fat pad mass was reduced by ~85% 
in mice treated with SCD1 ASO fed the SFA-rich diet, compared to control ASO treated 
mice (Supplemental Figure 2B). In agreement with previous reports7,8, dietary fish oil 
supplementation in control ASO-treated mice significantly reduced body weight gain, 
compared to control ASO-treated mice fed a SFA-rich diet (Supplemental Figure 2, A 
and B). It is important to point out that the effects of dietary fish oil and SCD1 ASO were 
not synergistic in reducing body weight. In addition to dramatic effects of adiposity, 
SCD1 ASO treatment significantly improved glucose tolerance in mice fed either diet 
(Supplemental Figure 2C). In control ASO treated mice, dietary fish oil modestly 
improved glucose tolerance, compared to SFA-feeding (Supplemental Figure 2C), 
regardless of ASO treatment. Furthermore, during insulin tolerance tests (ITT), SCD1 
ASO treated mice had enhanced blood glucose disposal, compared to control ASO 
treated mice on either diet, indicating enhanced insulin sensitivity (Supplemental Figure  
2D). However, the effects of dietary fish oil and SCD1 ASO were not synergistic in 
improving glucose and insulin tolerance. Collectively, these data support the notion9-21 
that SCD1 ASO treatment alone is extremely effective in the prevention of diet-induced 
obesity and insulin resistance, and that SCD1 inhibition in the presence of dietary fish oil 
does not provide synergistic protection.  
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Combined therapy of dietary fish oil and SCD1 ASO prevents diet-induced hepatic 
steatosis. Mice lacking SCD1 are protected against diet- and genetically-induced hepatic 
steatosis.13,14,17,20,21 Likewise, dietary ω-3 PUFA supplementation protects against hepatic 
steatosis in a number of experimental models.6,22 It remains possible that the anti-steatotic 
actions of fish oil may be attributable in part to its ability to downregulate the hepatic 
expression of SCD1 (Supplemental Figure 1A,6,7). As expected, in mice fed a SFA-rich 
diet, SCD1 ASO treatment alone resulted in striking reductions in hepatic neutral lipid 
accumulation (Supplemental Figure 4, A and B). In fact, in SFA-fed mice, SCD1 
inhibition reduced hepatic TG by 93% (Supplemental Figure 3A) and hepatic cholesteryl 
ester mass (CE) by 81% (Supplemental Figure 3B), compared to control ASO treated 
mice. Likewise, dietary fish oil supplementation decreased hepatic TG by 93-96% on 
both diets (Supplemental Figure 3A). After 20 weeks of treatment, the rank order for the 
groups in regards to hepatic TG levels was: SFA-fed/Control ASO (1409 mg/g protein) > 
Fish-fed/Control ASO (462 mg/g protein) > SFA-fed/SCD1 ASO (96 mg/g protein) > 
Fish-fed/SCD1 ASO (19 mg/g protein). In contrast to neutral lipids, hepatic phospholipid 
mass was not different among the four groups (Supplemental Figure 3C). As expected3,  
SCD1 ASO treatment caused a striking decrease in the oleate (18:1) to stearate (18:0) 
ratio in hepatic TG in both diet groups (Figure 3D). Dietary fish oil alone also caused a 
significant reduction in 18:1 to 18:0 ratio, compared to the dietary SFA group 
(Supplemental Figure 3D), in agreement with the previously described fish oil-driven 
reductions in hepatic SCD1 activity (Supplemental Figure 1C). In addition, dietary fish 
oil supplementation resulted in expected ω-3 PUFA-enrichment in hepatic TG 
(Supplemental Figure 3F). Interestingly, ASO-mediated inhibition of SCD1 in mice fed a 
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fish oil diet caused significantly more ω-3 PUFAs to be incorporated into hepatic TG, 
compared to control ASO treated mice. The reduction in hepatic TG seen with both 
dietary fish oil and SCD1 inhibition is likely due in part to both of these treatments 
causing robust downregulation of genes involved in de novo fatty acid synthesis.6,9 In 
support of this, both dietary fish oil and SCD1 ASO treatment caused dramatic decreases 
in lipogenic genes including fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), 
and mitochondrial glycerol-3-phosphate acyltransferase (mGPAT) to a similar degree 
(Supplemental Figure 3E). Unlike genetic deletion of SCD1 in mice fed a very low fat 
diet,23 SCD1 ASO treatment did not alter the expression of lecithin:cholesterol 
acyltransferase (LCAT) expression in mice fed either diet (Supplemental Figure 3E). 
Interestingly, both dietary fish oil and SCD1 ASO treatment caused an 81-86% decrease 
in hepatic expression of 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-CoA 
synthase) (Supplemental Figure 3E). As previously described3, SCD1 ASO treatment 
results in a ~2.2-fold increase in hepatic cholesterol 7alpha-hydroxylase (Cyp7α) 
expression, regardless of diet (Supplemental Figure 3E). Collectively, these data support  
previous observations that demonstrate both dietary fish oil and SCD1 inhibition are 
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Supplemental Table I. 
Fatty acid composition of diets (% of total FA)  
Fish Oil Diet       0.1      6.1       20.4     10.3      4.5       13.5        6.4      0.3         0.1       0.9     10.4      8.5      
Saturated Diet       2.0      6.4       31.7      0.7       6.1       24.4      17.9      0.5        0.2        0.5      0.5       0.5 
                                                                    18:1       18:2        18:3                     20:4     20:5     22:6   
  12:0      14:0       16:0      16:1     18:0      (n-9)       (n-6)       (n-3)      20:0      (n-6)     (n-3)     (n-3)   
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Supplemental Figure 1. Dietary and ASO-mediated regulation of SCD1 expression and function. Male LDLr -/-, 
ApoB100/100 mice were fed diets containing 0.1% (w/w) cholesterol enriched in either saturated (Sat.) or long 
chain ω-3 fatty acids (Fish) for 20 weeks in conjunction with biweekly injections (25 mg/kg) of a non-targeting 
control ASO  or SCD1 ASO . Relative quantification of SCD1 mRNA levels in the liver (A) or epididymal 
adipose tissue (B) was conducted by real-time qPCR, and normalized to cyclophilin. Data shown in panels A 
and B represent pooled RNA samples with n=5 mice per group. C. Hepatic SCD1 activity, data represent the 
mean ± SEM from 5 mice per group, and values not sharing a common superscript differ significantly (p < 0.05). 
 

























Supplemental Figure 2. Combination therapy of dietary fish oil and SCD1 ASO prevents diet-induced obesity 
and insulin resistance in LDLr-/-Apob100/100 mice. Starting at six weeks of age, mice were fed diets containing 
0.1% (w/w) cholesterol enriched in either saturated (Sat.) or long chain ω-3 fatty acids (Fish) for a period up to 
20 weeks in conjunction with biweekly injections (25 mg/kg) of either a non-targeting control (control) or SCD1 
ASO (SCD1). (A) Body weight, and (B) epididymal fat pad mass of mice following 20 weeks of diet and ASO 
treatment. Data in panel B represent the mean ± SEM from 8-15 mice per group, and values not sharing a 
common superscript differ significantly (p<0.05). Glucose tolerance tests (C) and insulin tolerance tests (D) were 
performed following 16 weeks of diet and ASO treatment. Data shown in panels C and D represent the mean ± 
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Supplemental Figure 3. Combined therapy of dietary fish oil and SCD1 ASO prevents diet-induced hepatic 
steatosis in LDLr -/-, ApoB100/100 mice. Starting at six weeks of age, male mice were fed diets containing 0.1% 
(w/w) cholesterol enriched in either saturated (Sat.) or long chain ω-3 fatty acids (Fish) for 20 weeks in 
conjunction with biweekly injections (25 mg/kg) of a non-targeting control ASO (Control) or SCD1 ASO (SCD1). 
Hepatic lipid mass measurements were conducted for A. triglyceride (TG), B. cholesteryl ester (CE), and C. 
phospholipids (PL). Data shown in panels A-C represent the mean ± SEM from 6-8 mice per group; values not 
sharing a common superscript differ significantly (p<0.05). D. Fatty acid (FA) composition [18:1 to 18:0 ratio or % 
of total FA as long chain ω-3 (eicosapentaenoic and decosahexaenoic) fatty acids] of hepatic triglycerides (TG-
FA). Data shown is panel D represents the mean ± SEM from 6-8 mice per group, and values not sharing a 
common superscript differ significantly (p<0.05). (E) Hepatic gene expression was measured in pooled samples 
(n=5 per pool) by qPCR, and normalized to cyclophilin. The mRNAs examined include: fatty acid synthase 
(FAS), acetyl-CoA carboxylase 1 (ACC1), mitochondrial glycerol-3-phosphate acyltransferase-1 (mGPAT), 
lecithin:cholesterol acyltransferase (LCAT), 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-Syn), 
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Supplemental Figure 4. Hepatic endoplasmic reticulum (ER) stress is not altered by diet or ASO treatment. 
Starting at six weeks of age, male mice were fed diets containing 0.1% (w/w) cholesterol enriched in either 
saturated (Sat.) or long chain ω-3 fatty acids (Fish) for 20 weeks in conjunction with biweekly injections (25 
mg/kg) of a non-targeting control ASO (Control) or SCD1 ASO (SCD1). ER stress was quantified by 
immunoblotting as described in materials and methods. The positive control (+) for this experiment represents 25 
µg of protein lysate from tunicamycin treated (10 µg/ml for 10 hours) elicited peritoneal macrophages, which 





















Supplemental Table II. Plasma cytokine levels following 20 weeks of diet and ASO treatment. Data 
represents the mean ± SEM (n = 5); N.D. = values not detectable. Values not sharing a common superscript 
differ significantly (p < 0.05). 
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